Bristol Myers Squibb stock popped Wednesday after the firm delayed a study testing Cobenfy in Alzheimer's disease psychosis.

Bristol-Myers Squibb shares gained after the company announced that it will enroll additional patients in the ADEPT-2 study.

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

CHONGQING, CHINA - APRIL 20: In this photo illustration, the Bristol Myers Squibb logo is displayed on a smartphone screen, with the company's signature purple branding in the background, on April 20, ...

Wondering if Bristol-Myers Squibb is a bargain or overpriced? Let’s dig into what’s behind the numbers so you can decide with ...

While the S&P 500 is up 16.3% since May 2025, Bristol-Myers Squibb (currently trading at $48.73 per share) has lagged behind, posting a return of 10.4%. This might have investors contemplating their ...

Share price of Bristol Myers Squibb (BMY) touched a 52-week low of $42.96 on July 31, post its second-quarter earnings release. The stock has recovered 6.7% since then and is currently trading at ...

If you are looking to own a stock for the long term, these out-of-favor drugmakers have proven they have what it takes to ...

We came across a bullish thesis on Bristol-Myers Squibb Company on CompoundingLab’s Substack. In this article, we will ...

Bristol Myers will enroll more patients in its Cobenfy Alzheimer's psychosis study after site irregularities, with ...